Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) has announced its participation in the 44th Annual Canaccord Growth Conference. The company's senior management will present a company overview on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.

Investors and interested parties can access a webcast of the event through the Events and Presentations link on the Investors page of Verona Pharma's website, www.veronapharma.com. This presentation provides an opportunity for the company to showcase its progress and future plans to a wider audience of potential investors and industry professionals.

For those seeking additional information, Verona Pharma has provided contact details for investor relations, US investor enquiries, and international/US media enquiries.

News Market Reaction

-2.57%

1 alert

-2.57% News Effect

On the day this news was published, VRNA declined 2.57%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44^th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.

A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc	Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications	IR@veronapharma.com
Argot Partners (US Investor Enquiries)	Tel: +1-212-600-1902 verona@argotpartners.com
Ten Bridge Communications International / US Media Enquiries	Tel: +1-312-523-5016 tbcverona@tenbridgecommunications.com
Leslie Humbel

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre^TM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

FAQ

When is Verona Pharma (VRNA) presenting at the Canaccord Growth Conference?

Verona Pharma (VRNA) is presenting at the 44th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.

How can investors watch Verona Pharma's (VRNA) presentation at the Canaccord conference?

Investors can watch a webcast of Verona Pharma's (VRNA) presentation through the Events and Presentations link on the Investors page of the company's website, www.veronapharma.com.

What is the purpose of Verona Pharma's (VRNA) participation in the Canaccord Growth Conference?

Verona Pharma's (VRNA) participation in the Canaccord Growth Conference allows the company to present a company overview, showcasing its progress and future plans to potential investors and industry professionals.

Who should I contact for investor relations inquiries about Verona Pharma (VRNA)?

For investor relations inquiries about Verona Pharma (VRNA), you can contact Victoria Stewart, Senior Director of Investor Relations and Communications, at IR@veronapharma.com or call +1-844-341-9901.